In this enlightening discussion, Dr. Altan Ahmed from Moffitt Cancer Center and Dr. Sid Padia from UCLA delve into the innovative HEPZATO treatment for liver metastases from uveal melanoma. They explore patient selection for clinical trials and the intricacies of the treatment procedure. The conversation highlights the importance of teamwork in optimizing workflow and drug dosing, as well as the need for ongoing research to address current gaps. They also discuss future applications for HEPZATO in treating other malignancies, promising new hope for patients.